Compare RM & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RM | PEPG |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 396.7M | 317.6M |
| IPO Year | 2012 | 2022 |
| Metric | RM | PEPG |
|---|---|---|
| Price | $37.31 | $5.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $30.00 | $9.50 |
| AVG Volume (30 Days) | 52.1K | ★ 763.9K |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | ★ 3.21% | N/A |
| EPS Growth | ★ 71.26 | N/A |
| EPS | ★ 4.13 | N/A |
| Revenue | ★ $610,145,000.00 | N/A |
| Revenue This Year | $16.06 | N/A |
| Revenue Next Year | $6.56 | N/A |
| P/E Ratio | $9.04 | ★ N/A |
| Revenue Growth | ★ 9.60 | N/A |
| 52 Week Low | $25.41 | $0.88 |
| 52 Week High | $46.00 | $6.85 |
| Indicator | RM | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 44.65 | 54.02 |
| Support Level | $35.93 | $5.41 |
| Resistance Level | $39.68 | $6.72 |
| Average True Range (ATR) | 1.45 | 0.56 |
| MACD | 0.10 | 0.03 |
| Stochastic Oscillator | 37.15 | 42.63 |
Regional Management Corp is a diversified consumer finance company that provides installment loan products to customers with limited access to consumer credit from banks, thrifts, credit card companies, and other lenders. It is engaged in consumer finance. The company has the core products which are small and large installment loans. The company also offers optional payment and collateral protection insurance. The company's principal source of revenue is interest and fee income on outstanding loans.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.